North Carolina State University’s College of Veterinary Medicine is one of several centers across the country participating in a study of canine epilepsy, the most common neurological disorder in dogs. Goals include generating a clearer understanding of the condition and developing pathways to treatment. The centers are looking for canine patients to include in the study. Eligible dogs have to meet specific age and treatment history criteria, but they can be of any breed. American City Business Journals/Raleigh/Durham, N.C./Traingle BizBlog (8/15
For the more than 780,000 dogs diagnosed with canine epilepsy each year, an ongoing study at North Carolina State University could offer relief.
North Carolina State University’s College of Veterinary Medicine is among investigator sites participating in a nationwide canine epilepsy clinical trial. Epilepsy is the single most common neurological disorder in dogs, and researchers still haven’t identified a cause. That’s where the national study comes in, aiming to provide important evidence-based research that could lead to improved understanding, as well as new treatment options.
To qualify for the trial, dogs must be at least 4 months of age, have received no more of 7 days of prior treatment with an anti-seizure medication, and meet certain other requirements. All breeds are eligible.
Dog owners will net up to $150 to help with travel-related expenses.
All medical care, including physical and neurological exams, blood and urine testing, MRI and medication, will be offered free of charge to participating canines. The study is sponsored by an unnamed major animal health pharmaceutical company and is regulated by the U.S. Food and Drug Administration. Enrollment of patients is expected to run into 2014 and additional study sites are located in California, Colorado, Florida, Illinois, Kansas, Massachusetts, Main, New Jersey, New York, Pennsylvania, South Carolina and Tennessee. Raleigh-based Raleigh-based Visionaire Research & Education is recruiting for the trial.
Leave a Reply